Crossmark

Association of the Tyrosine/Nitrotyrosine pathway with death or ICU admission within 30 days for patients with community acquired pneumonia

Crossref DOI link: https://doi.org/10.1186/s12879-018-3335-y

Published Online: 2018-08-24

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Baumgartner, Thomas https://orcid.org/0000-0002-6782-0893
Zurauskaité, Giedré

Wirz, Yannick

Meier, Marc

Steuer, Christian

Bernasconi, Luca

Huber, Andreas

Christ-Crain, Mirjam

Henzen, Christoph

Hoess, Claus

Thomann, Robert

Zimmerli, Werner

Mueller, Beat

Schuetz, Philipp
Funding

Funding for this research was provided by:

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_150531)

Forschungsrat Kantonsspital Aarau (1410.000.058, 1410.000.044)
License Information

Text and Data Mining valid from 2018-08-24
More Information

Article History

Received: 12 December 2017

Accepted: 15 August 2018

First Online: 24 August 2018

Ethics approval and consent to participate

: The initial study protocol has been performed in accordance with the declaration of Helsinki and was approved by the ethics committee of the University of Basel, written informed consent for the study including consent for the use of the data in secondary blood marker analyses and follow-up was obtained from all participating patients. The trial was registered at(identifier ISRCTN95122877).

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.